Zentalis Pharmaceuticals Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Julie Eastland
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08CEO
Julie Eastland (60 yo)
less than a year
Tenure
Ms. Julie M. Eastland is CEO, President & Director of Zentalis Pharmaceuticals, Inc. from November 12, 2024. Ms. Eastland joined the Zentalis Pharmaceuticals, Inc. on November 12, 2024. She serves as Indep...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Legal Officer & Corporate Secretary | 2.3yrs | US$2.63m | 0.0097% $ 22.2k | |
| CEO, President & Director | less than a year | no data | no data | |
| VP of Finance & Interim Principal Accounting Officer | less than a year | no data | 0.048% $ 109.0k | |
| Chief Scientific Officer | 1.1yrs | no data | 0.0035% $ 8.0k | |
| Chief People Officer | no data | no data | no data | |
| Chief Strategy Officer | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Business Officer | no data | no data | no data |
0.4yrs
Average Tenure
49yo
Average Age
Experienced Management: ZNTL's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | no data | |
| Chairman of the Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$515.22k | 0.067% $ 154.5k | |
| Independent Director | 4.9yrs | US$617.78k | 0.20% $ 464.9k | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.8yrs | US$516.97k | 0.054% $ 123.0k | |
| Independent Director | 7yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data |
2.1yrs
Average Tenure
54yo
Average Age
Experienced Board: ZNTL's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:04 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zentalis Pharmaceuticals, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Biren Amin | Jefferies LLC |